[go: up one dir, main page]

CO4700289A1 - Antagonistas de taquicinina amida que tienen actividad antagonista de taquicinina - Google Patents

Antagonistas de taquicinina amida que tienen actividad antagonista de taquicinina

Info

Publication number
CO4700289A1
CO4700289A1 CO95058767A CO95058767A CO4700289A1 CO 4700289 A1 CO4700289 A1 CO 4700289A1 CO 95058767 A CO95058767 A CO 95058767A CO 95058767 A CO95058767 A CO 95058767A CO 4700289 A1 CO4700289 A1 CO 4700289A1
Authority
CO
Colombia
Prior art keywords
tachycinin
amida
antagonists
sulfur
methyl
Prior art date
Application number
CO95058767A
Other languages
English (en)
Inventor
So Young Ko
Christopher Walpole
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9425085.9A external-priority patent/GB9425085D0/en
Priority claimed from GBGB9426016.3A external-priority patent/GB9426016D0/en
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of CO4700289A1 publication Critical patent/CO4700289A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

1. UN COMPUESTO DE LA FORMULA I FIGURA 1 EN LA QUE R1 ES FENILO MONO O DISUSTITUIDO POR UNO O DOS MIEMBROS SELECCIONADOS DEL GRUPO QUE CONSISTE DE HALOGENO, NITRO, CIANO, TRIFLUOROMETILO, HIDROZI, METOXI, HIDROXIMETILO, METOXIMETILO, METOXICARBO- LO, CARBAMOILO Y N-METILCARBAMOILO, n ES CERO o 1 X1 ES OXIGENO, AZUFRE O =NCN, X2 Y X3 SON CADA UNO INDEPENDIENTEMENTE OXIGENO O AZUFRE, R2 ES HIDROGENO O METILO, R3 ES FENILO, FENILO SUSTITUIDO CON HALO, 2-NAFTI- LO, 1H-INDOL-3-ILO O 1-METIL-INDOL-3-ILO, Z ES -N(CH3)o -CH2-, R4 ES FENILO, 3,5-BIS(TRIFLUOROMETIL)FENILO O PI- RIDILO, Y R5 ES HIDROGENO, FENILO 3,5-BIS(TRIFLUOROMETIL) FENILO O PIRIDILO, POR LO QUE, CUANDO X3 ES AZUFRE, Z ES -N(CH3)-, O UNA SAL DE ADICION DE ACIDO DEL MISMO.
CO95058767A 1994-12-13 1995-12-12 Antagonistas de taquicinina amida que tienen actividad antagonista de taquicinina CO4700289A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9425085.9A GB9425085D0 (en) 1994-12-13 1994-12-13 Organic compounds
GBGB9426016.3A GB9426016D0 (en) 1994-12-22 1994-12-22 Organic compounds

Publications (1)

Publication Number Publication Date
CO4700289A1 true CO4700289A1 (es) 1998-12-29

Family

ID=26306161

Family Applications (1)

Application Number Title Priority Date Filing Date
CO95058767A CO4700289A1 (es) 1994-12-13 1995-12-12 Antagonistas de taquicinina amida que tienen actividad antagonista de taquicinina

Country Status (17)

Country Link
EP (1) EP0797583A1 (es)
JP (1) JPH10511935A (es)
AR (1) AR001332A1 (es)
AU (1) AU4343796A (es)
BR (1) BR9509997A (es)
CA (1) CA2204130A1 (es)
CO (1) CO4700289A1 (es)
CZ (1) CZ179097A3 (es)
FI (1) FI971685L (es)
HU (1) HUT77002A (es)
IL (1) IL116323A0 (es)
NO (1) NO972526D0 (es)
PE (1) PE38997A1 (es)
PL (1) PL320217A1 (es)
SK (1) SK74697A3 (es)
TR (1) TR199501568A2 (es)
WO (1) WO1996018643A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998015277A2 (en) * 1996-10-07 1998-04-16 Merck Sharp & Dohme Limited Cns-penetrant nk-1 receptor antagonists as antidepressant and/or an anti-anxiety agents
US6117855A (en) 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
KR100699404B1 (ko) 1999-02-18 2007-03-23 가켄 세야쿠 가부시키가이샤 성장 호르몬 분비촉진제로서의 신규 아미드 유도체
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
BR0015320A (pt) 1999-11-03 2002-07-09 Albany Molecular Res Inc Composto, composição, métodos de tratamento de um distúrbio que e criado pela, ou é dependente da, disponibilidade diminuìda de serotonina, norepinefrina ou dopamina, para inibir a captação da serotonina, da dopamina e de norepinefrina sinápticas em um paciente em necessidade destes, e, kit
CN100430401C (zh) 2000-07-11 2008-11-05 Amr科技公司 新的4-苯基取代的四氢异喹啉类化合物及其治疗用途
UA91341C2 (ru) 2004-07-15 2010-07-26 Амр Текнолоджи, Інк. Арил- и гетероарилзамещенные тетрагидроизохинолины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
JP5258561B2 (ja) 2005-07-15 2013-08-07 アルバニー モレキュラー リサーチ， インコーポレイテッド アリール置換およびヘテロアリール置換テトラヒドロベンズアゼピンならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するためのその使用
BRPI0616463A2 (pt) 2005-09-29 2011-06-21 Merck & Co Inc composto, composição farmacêutica, e, uso de um composto
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2083831B1 (en) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
JP4611444B2 (ja) 2007-01-10 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール
JP2010516731A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド ２−メトキシ−５−（５−トリフルオロメチル−テトラゾール−１−イル）−ベンジル］−（２ｓ−フェニル−ピペリジン−３ｓ−イル）−アミンを含む医薬組成物
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
CN102014631A (zh) 2008-03-03 2011-04-13 泰格尔医药科技公司 酪氨酸激酶抑制剂
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
EP2429296B1 (en) 2009-05-12 2017-12-27 Albany Molecular Research, Inc. 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
AU2010247849B2 (en) 2009-05-12 2015-11-19 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
US8815894B2 (en) 2009-05-12 2014-08-26 Bristol-Myers Squibb Company Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
JP5099731B1 (ja) 2009-10-14 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション ｐ５３活性を増大する置換ピペリジン及びその使用
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
US9029341B2 (en) 2010-08-17 2015-05-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
WO2012027236A1 (en) 2010-08-23 2012-03-01 Schering Corporation NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
US20140045832A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Insulin-Like Growth Factor-1 Receptor Inhibitors
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP2844261B1 (en) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
CA2882950A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
MX363243B (es) 2012-11-28 2019-03-14 Merck Sharp & Dohme Composiciones para tratar cáncer y usos de dichas composiciones.
TW201429969A (zh) 2012-12-20 2014-08-01 Merck Sharp & Dohme 作爲ｈｄｍ２抑制劑之經取代咪唑吡啶
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
EP3525785A4 (en) 2016-10-12 2020-03-25 Merck Sharp & Dohme Corp. KDM5 INHIBITORS
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
CN112805006B (zh) 2018-08-07 2024-09-24 默沙东有限责任公司 Prmt5抑制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164372A (en) * 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
JPH05186498A (ja) * 1991-12-27 1993-07-27 Japan Tobacco Inc プロリン誘導体

Also Published As

Publication number Publication date
BR9509997A (pt) 1997-12-30
JPH10511935A (ja) 1998-11-17
HUT77002A (hu) 1998-03-02
TR199501568A2 (tr) 1996-07-21
IL116323A0 (en) 1996-03-31
PL320217A1 (en) 1997-09-15
WO1996018643A1 (en) 1996-06-20
NO972526L (no) 1997-06-03
NO972526D0 (no) 1997-06-03
FI971685L (fi) 1997-08-13
AR001332A1 (es) 1997-10-22
EP0797583A1 (en) 1997-10-01
AU4343796A (en) 1996-07-03
PE38997A1 (es) 1997-10-02
CZ179097A3 (en) 1997-10-15
SK74697A3 (en) 1997-11-05
FI971685A0 (fi) 1997-04-18
CA2204130A1 (en) 1996-06-20
MX9703957A (es) 1997-09-30

Similar Documents

Publication Publication Date Title
CO4700289A1 (es) Antagonistas de taquicinina amida que tienen actividad antagonista de taquicinina
DE59108530D1 (de) Antimikrobielle Mittel sowie substituierte 2-Cyclohexan-1-yl-amin-Derivate und deren Herstellung
ATE167470T1 (de) Heterocyclische amine zur therapie von asthma und entzündungen der atemwege
IL135333A0 (en) Acylsulfamoyl benzoic acid amides, plant protection agents containing said acylsulfamoyl benzoic acid amides, and method for producing the same
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
DE3868076D1 (de) Heterocyclische derivate, verfahren zu ihrer herstellung und diese derivate als aktive bestandteile enthaltende fungizide.
YU74892A (sh) Novi herbicidi
NO952397L (no) Substituerte pyrazoler som CRF antagonister
ATE180773T1 (de) N-sulfonyl-2-oxoindol-derivate mit einer affinität für die vasopressin und/oder ocytocin rezeptoren
DE69203104D1 (de) Herstellung von zellularen Elastomeren und chemische Zusammensetzungen zu deren Herstellung.
FI974447A0 (fi) Semikarbatsonit, joilla on keskushermostoaktiivisuutta, ja niitä sisältävät farmaseuttiset valmisteet
ATE156818T1 (de) Polyfluoralkylthiopoly(ethylimidazolium)- verbindungen, verfahren zu ihrer herstellung und ihre verwendung als biozide mittel
ES2056783T3 (es) Derivados sustituidos del acido benzoico con actividad cardiovascular.
ATE180781T1 (de) Kristallines tiagabinehydrochlorid-monohydrat, seine herstellung und verwendung
ATE81344T1 (de) 2,3-disubstituierte isoxazolidine, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung.
ATE11134T1 (de) 1-(3-halogen-2-pyridinyl)piperazine, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
PT861250E (pt) Derivados de amidina e de isotioureia como inibidores de oxido nitrico sintase
ATE37182T1 (de) Imidazolinone und imidazolidinthione, verfahren zu deren herstellung und verwendung dieser verbindungen als herbizide.
EP0330826A3 (de) Verwendung von Pyridin-2-ethern beziehungsweise Pyridin-2-thioethern mit einem stickstoffhaltigen cycloaliphatischen Ring als antidepressiv wirkende Arzneimittel
CO4761039A1 (es) Mezclas fungicidas que contienen carbamatos y amidas de acido carboxilico
ES8305316A1 (es) Un procedimiento para la preparacion de guanidinas.
ATE144510T1 (de) N-(isochinolein-5-yl)-sulfonyl azazykloalkane, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
PT782574E (pt) Carboxamidas biciclicas como antagonistas 5-ht1a
ATE123776T1 (de) Aminoalkylchromone, verfahren zu ihrer herstellung und diese enthaltende zusammensetzungen.
DE3574588D1 (de) N-benzoyl-n'-pyrimidinyloxyphenyl-harnstoffverbindungen, diese enthaltende antitumorische zusammenstellungen und verfahren zu deren herstellung.